Covid-19 in patients with inflammatory bowel diseases: rates and courses of infection, rates of vaccination, potential side effects and antibody titers - An evaluation at the outpatient clinic for IBD of the University Hospital Heidelberg
- Conditions
- Covid-19Inflammatory Bowel Diseases
- Registration Number
- DRKS00027218
- Lead Sponsor
- niversitätsklinikum Heidelberg
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
a) Patient with ulcerative colitis or Crohn's disease reliably diagnosed according to the criteria of the DGVS (German Society for Digestive and Metabolic Diseases)
b) Age from 18 years
d) Treatment in the Department of Internal Medicine IV of the Heidelberg University Hospital at the time of sample collection
e) The patient is able to give consent.
f) Signed declaration of consent
Exclusion Criteria
Failure to meet the inclusion criteria
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The main objectives of the project are:<br>1. to record the prevalence of SARS-CoV2 infection in our IBD cohort,<br>2. Describe the severity of any SARS-CoV2 infections you may have had (hospitalization, intensive care treatment),<br>3. to record the vaccination rates against SARS-CoV2 in our cohort,<br>4. Describe the serological response (S and N antibodies) to SARS-CoV2 infection and vaccinations at different times, and<br>5. To record possible side effects of the vaccinations, especially with regard to the course of IBD.
- Secondary Outcome Measures
Name Time Method In a further step, possible connections between disease activity of IBD, immunosuppressive therapy and both the severity of a possible SARS-CoV2 infection and the serological vaccination response are to be established. (knowing that the informative value of a serological evaluation alone is limited).